We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

By LabMedica International staff writers
Posted on 18 Sep 2026

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. More...

Routine blood tests may produce borderline results that are hard to interpret in isolation, while changes over time can reveal patterns that a single measurement may miss. A new study now shows that tracking trends in common blood tests alongside unexplained weight loss can help identify patients at increased risk of cancer and support earlier investigation.

Researchers at the University of Oxford evaluated patterns over time in 26 commonly used primary care blood tests among patients with unexplained weight loss. The approach examined changes across repeat measurements, rather than relying solely on whether a single result was abnormal. The study, published September 17 in PLOS Medicine, tested whether temporal trends improved risk stratification for overall and site‑specific cancers compared with abnormalities on single tests.

The analysis included more than 275,000 patients, among whom nearly 14,000 were diagnosed with cancer within six months. Investigators related both individual abnormal results and longitudinal trends to subsequent cancer diagnoses. Abnormal values such as low hemoglobin or increased platelet counts were recognized as potential indicators, and the study specifically examined whether monitoring trends could uncover cancer‑related changes that remained within conventional reference ranges.

Overall, 23 blood test trends were associated with elevated risk of any cancer. After accounting for age and sex, several trends were more discriminative for cancer diagnosis than single abnormal results. Examples included trends in white blood cell (WBC) count and neutrophils linked to lung cancer, and trends in red blood cell (RBC) count, hematocrit, and the platelet‑to‑lymphocyte ratio associated with prostate cancer. The authors state that incorporating patterns of blood test abnormalities with unexplained weight loss could help identify primary care patients who should undergo additional cancer testing.

“We show how blood test results are made more accurate for cancer by adding patient age and sex. This relatively simple calculation could easily be performed at the laboratory,” said Brian Nicholson, study author.

“In some instances, monitoring how a patient's blood test results change over time could offer further value. We plan to assess how well blood test abnormalities and trends inform cancer risk in patients with other types of non-specific symptoms, such as fatigue and vomiting,” stated Pradeep Virdee, study author.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.